The KRAS in-colorectal-cancer collaborative group (RASCAL II) study has shown that a glycine to valine mutation on codon 12 of the KRAS gene is aggressive in patients with Duke's C CRC [49]. This evidence concerns the gene KRAS and colorectal cancer.